Provectus Biopharmaceuticals Inc (PVCT)

[Wehalls]

From the conclusions on the Poster.
PV-10, an IL immunotherapeutic agent, demonstrates significant anti-tumor activity in
HNSCC.
• Our In vitro studies show PV-10 induces potent ICD in HNSCC cells.
• Our In vivo experiments show IL PV-10 lead to substantial tumor regression and complete
responses in some mice.
• These findings underscore the significance of PV-10-induced ICD which may offer a novel
and promising approach for managing HNSCC and potentially pave the way for improved
survival rates and reduced adverse events